Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 8, 2012, Pages 1316-1323

  Yue, Hong ^a,e   Tanaka, Kuniyoshi ^b,f   Furukawa, Tatsuhiko ^c   Karnik, Sadashiva S ^a,d   Li, Wei ^a,b,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FUKUI   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

STAT3; Thymidine phosphorylase; Vascular smooth muscle cell proliferation

Indexed keywords

PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; STAT3 PROTEIN; THYMIDINE PHOSPHORYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; JANUS KINASE 2; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; THYMIDINE PHOSPHORYLASE; UP-REGULATION;

RATTUS;

EID: 84862270511     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.05.025     Document Type: Article

References (59)

1. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakama M., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5855-5859.
2. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., von der Leyen H., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest. 1994, 93:1458-1464.
3. Simons M., Edelman E.R., DeKeyser J.L., Langer R., Rosenberg R.D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992, 359:67-70.
4. Barton G.J., Ponting C.P., Spraggon G., Finnis C., Sleep D. Human platelet-derived endothelial cell growth factor is homologous to Escherichia coli thymidine phosphorylase. Protein Sci. 1992, 1:688-690.
5. Li W., Tanaka K., Ihaya A., Fujibayashi Y., Takamatsu S., Morioka K., Sasaki M., Uesaka T., Kimura T., Yamada N., Tsuda T., Chiba Y. Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H408-H415.
6. Li W., Tanaka K., Morioka K., Takamori A., Handa M., Yamada N., Ihaya A. Long-term effect of gene therapy for chronic ischemic myocardium using platelet-derived endothelial cell growth factor in dogs. J. Gene Med. 2008, 10:412-420.
7. Yamada N., Li W., Ihaya A., Kimura T., Morioka K., Uesaka T., Takamori A., Handa M., Tanabe S., Tanaka K. Platelet-derived endothelial cell growth factor gene therapy for limb ischemia. J. Vasc. Surg. 2006, 44:1322-1328.
8. Li W., Tanaka K., Morioka K., Uesaka T., Yamada N., Takamori A., Handa M., Tanabe S., Ihaya A. Thymidine phosphorylase gene transfer inhibits vascular smooth muscle cell proliferation by upregulating heme oxygenase-1 and p27KIP1. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1370-1375.
9. Handa M., Li W., Morioka K., Takamori A., Yamada N., Ihaya A. Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft. J. Vasc. Surg. 2008, 48:1566-1574.
10. Baetta R., Soma M., De-Fraja C., Comparato C., Teruzzi C., Magrassi L., Cattaneo E. Upregulation and activation of Stat6 precede vascular smooth muscle cell proliferation in carotid artery injury model. Arterioscler. Thromb. Vasc. Biol. 2000, 20:931-939.
11. Kundumani-Sridharan V., Wang D., Karpurapu M., Liu Z., Zhang C., Dronadula N., Rao G.N. Suppression of activation of signal transducer and activator of transcription-5B signaling in the vessel wall reduces balloon injury-induced neointima formation. Am. J. Pathol. 2007, 171:1381-1394.
12. Kusch A., Tkachuk S., Haller H., Dietz R., Gulba D.C., Lipp M., Dumler I. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J. Biol. Chem. 2000, 275:39466-39473.
13. Torella D., Curcio A., Gasparri C., Galuppo V., De Serio D., Surace F.C., Cavaliere A.L., Leone A., Coppola C., Ellison G.M., Indolfi C. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2935-H2943.
14. Wang T.H., Xiang Q.L., Chen J.W., Pan H., Cui Y.H. Raloxifene plus 17beta-estradiol inhibits proliferation of primary cultured vascular smooth muscle cells and human mammary endothelial cells via the janus kinase/signal transducer and activator of transcription3 cascade. Eur. J. Pharmacol. 2007, 561:7-13.
15. Kusch A., Tkachuk S., Tkachuk N., Patecki M., Park J.K., Dietz R., Haller H., Dumler I. The tight junction protein ZO-2 mediates proliferation of vascular smooth muscle cells via regulation of Stat1. Cardiovasc. Res. 2009, 83:115-122.
16. Stephanou A., Latchman D.S. Opposing actions of STAT-1 and STAT-3. Growth Factors 2005, 23:177-182.
17. Bai Y., Ahmad U., Wang Y., Li J.H., Choy J.C., Kim R.W., Kirkiles-Smith N., Maher S.E., Karras J.G., Bennett C.F., Bothwell A.L., Pober J.S., Tellides G. Interferon-gamma induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation. J. Biol. Chem. 2008, 283:6832-6842.
18. Li W., Febbraio M., Reddy S.P., Yu D.Y., Yamamoto M., Silverstein R.L. CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J. Clin. Investig. 2010, 120:3996-4006.
19. Yue H., Lee J.D., Shimizu H., Uzui H., Mitsuke Y., Ueda T. Effects of magnesium on the production of extracellular matrix metalloproteinases in cultured rat vascular smooth muscle cells. Atherosclerosis 2003, 166:271-277.
20. Miyadera K., Sumizawa T., Haraguchi M., Yoshida H., Konstanty W., Yamada Y., Akiyama S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 1995, 55:1687-1690.
21. Yue H., Li W., Desnoyer R., Karnik S.S. Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovasc. Res. 2010, 85:90-99.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
23. Chen K., Febbraio M., Li W., Silverstein R.L. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ. Res. 2008, 102:1512-1519.
24. Chen K., Li W., Major J., Rahaman S.O., Febbraio M., Silverstein R.L. Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. Blood 2011, 117:5744-5750.
25. Li W., Tanaka K., Chiba Y., Kimura T., Morioka K., Uesaka T., Ihaya A., Sasaki M., Tsuda T., Yamada N. Role of MMPs and plasminogen activators in angiogenesis after transmyocardial laser revascularization in dogs. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H23-H30.
26. Nilsson J., Bjursell G., Kannius-Janson M. Nuclear Jak2 and transcription factor NF1-C2: a novel mechanism of prolactin signaling in mammary epithelial cells. Mol. Cell. Biol. 2006, 26:5663-5674.
27. Zouein F.A., Duhe R.J., Booz G.W. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors 2011, 29:245-252.
28. Mlinaric-Rascan I., Yamamoto T. B cell receptor signaling involves physical and functional association of FAK with Lyn and IgM. FEBS Lett. 2001, 498:26-31.
29. Rane S.G., Reddy E.P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002, 21:3334-3358.
30. Wang L., Kurosaki T., Corey S.J. Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway. Oncogene 2007, 26:2851-2859.
31. Hunter T. A tail of two src's: mutatis mutandis. Cell 1987, 49:1-4.
32. Martin G.S. The hunting of the Src. Nat. Rev. Mol. Cell Biol. 2001, 2:467-475.
33. Yang J., Stark G.R. Roles of unphosphorylated STATs in signaling. Cell Res. 2008, 18:443-451.
34. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007, 21:1396-1408.
35. Yang J., Chatterjee-Kishore M., Staugaitis S.M., Nguyen H., Schlessinger K., Levy D.E., Stark G.R. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 2005, 65:939-947.
36. Pena G., Cai B., Liu J., van der Zanden E.P., Deitch E.A., de Jonge W.J., Ulloa L. Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis. Eur. J. Immunol. 2010, 40:2580-2589.
37. Fearon I.M., Faux S.P. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J. Mol. Cell. Cardiol. 2009, 47:372-381.
38. Morishita R., Sugimoto T., Aoki M., Kida I., Tomita N., Moriguchi A., Maeda K., Sawa Y., Kaneda Y., Higaki J., Ogihara T. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat. Med. 1997, 3:894-899.
39. Boyle J.J., Wilson B., Bicknell R., Harrower S., Weissberg P.L., Fan T.P. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J. Pathol. 2000, 192:234-242.
40. Sluimer J.C., Daemen M.J. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J. Pathol. 2009, 218:7-29.
41. Li D.Y., Brooke B., Davis E.C., Mecham R.P., Sorensen L.K., Boak B.B., Eichwald E., Keating M.T. Elastin is an essential determinant of arterial morphogenesis. Nature 1998, 393:276-280.
42. Daniel J.M., Dutzmann J., Bielenberg W., Widmer-Teske R., Gunduz D., Hamm C.W., Sedding D.G. Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res. Cardiol. 2012, 107:1-12.
43. Hui D.Y. Intimal hyperplasia in murine models. Curr. Drug Targets 2008, 9:251-260.
44. Lufei C., Koh T.H., Uchida T., Cao X. Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 2007, 26:7656-7664.
45. Seidel H.M., Lamb P., Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 2000, 19:2645-2656.
46. Pertel T., Zhu D., Panettieri R.A., Yamaguchi N., Emala C.W., Hirshman C.A. Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L492-L500.
47. Harder K.W., Parsons L.M., Armes J., Evans N., Kountouri N., Clark R., Quilici C., Grail D., Hodgson G.S., Dunn A.R., Hibbs M.L. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 2001, 15:603-615.
48. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
49. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
50. Epling-Burnette P.K., Zhong B., Bai F., Jiang K., Bailey R.D., Garcia R., Jove R., Djeu J.Y., Loughran T.P., Wei S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J. Immunol. 2001, 166:7486-7495.
51. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
52. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., Irby R., Yeatman T., Courtneidge S.A., Jove R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7319-7324.
53. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
54. Thirunavukkarasu M., Juhasz B., Zhan L., Menon V.P., Tosaki A., Otani H., Maulik N. VEGFR1 (Flt-1+/-) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free Radic. Biol. Med. 2007, 42:1487-1495.
55. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L.M., Karras J., Bromberg J., Pardoll D., Jove R., Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
56. Shih R.H., Lee I.T., Hsieh H.L., Kou Y.R., Yang C.M. Cigarette smoke extract induces HO-1 expression in mouse cerebral vascular endothelial cells: involvement of c-Src/NADPH oxidase/PDGFR/JAK2/STAT3 pathway. J. Cell. Physiol. 2010, 225:741-750.
57. Levy D.E., Lee C.K. What does Stat3 do?. J. Clin. Investig. 2002, 109:1143-1148.
58. Brown S., Zeidler M.P. Unphosphorylated STATs go nuclear. Curr. Opin. Genet. Dev. 2008, 18:455-460.
59. Meyer T., Begitt A., Lodige I., van Rossum M., Vinkemeier U. Constitutive and IFN-gamma-induced nuclear import of STAT1 proceed through independent pathways. EMBO J. 2002, 21:344-354.